2028 Competition Pharma 
PM360
JANUARY 24, 2025
For the past nine years, EVERSANA INTOUCH has done a look ahead: a forecast based on input from leaders on what trends may shape pharma marketing in the year ahead. Lets take a closer look at each of these trends: Applied AI: As excitement continues to grow and AI becomes more real, how is it being deployed by pharma marketers?
Pharmaceutical Technology
SEPTEMBER 15, 2022
The top 13 players reported more than 10% revenue growth, with BioNTech (3,834.4%), Moderna (2,199.1%), Pfizer (95.2%) and Regeneron Pharmaceuticals (89.1%) reporting a more than 80% year-on-year (YoY) revenue growth from 2020 to 2021, according to GlobalData’s Pharma Intelligence Centre Companies Database. AbbVie reported a 22.7%
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
AUGUST 4, 2022
The deal comes as Amgen has been under pressure from competition to its big-selling arthritis therapy Enbrel (etanercept) and blood cell booster Epogen (epoetin alfa), and a patent expiry for psoriasis blockbuster Otezla (apremilast) in 2028. Amgen said it expects the deal to close in the fourth quarter of 2022.
European Pharmaceutical Review
SEPTEMBER 14, 2023
Ultimately, this puts European businesses at a competitive disadvantage compared to other companies worldwide. Once adopted by the Council, the regulatory proposals are planned to come into force on 1 July 2028 (for BEFIT) and on 1 January 2026 (for the transfer pricing proposal).
pharmaphorum
AUGUST 2, 2022
Now, Roche has an opportunity to add ease of administration to the competitive profile of Tecentriq, reducing the time patients have to spend in clinics and potentially reducing the cost of treatment. Results from a trial in first-line NSCLC are due in early 2023.
PM360
SEPTEMBER 21, 2023
Attention deficit hyperactivity disorder (ADHD) drug Vyvanse (lisdexamfetamine dimesylate) , manufactured by Takeda, also is facing generic competition. In the respiratory area with inhalers, it’s tough to get drugs approved, so the competition comes slowly,” he said. Starting in 2026, the provision will affect 10 Part D drugs.
Pharmaceutical Representative Training
JANUARY 29, 2025
These high prices are the result of multiple factors: theyre derived from living organisms making them sensitive and complex for both manufacturers and patients, research requires advanced technology to test for safety and effectiveness, and theyre in high demand without much competition. Starting in 2019, the US market was valued at $4.5
Expert insights. Personalized for you.
52 
Let's personalize your content